FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2107436520> ?p ?o ?g. }

• W2107436520 endingPage "e54" @default.
• W2107436520 startingPage "e54" @default.
• W2107436520 abstract "Kostmann's syndrome is a congenital disorder that causes an impairment of myeloid differentiation in the bone marrow characterized by severe neutropenia, which can be treated with recombinant human granulocyte colony-stimulating factor (G-CSF). We present the case of a 13-year-old boy with Kostmann's syndrome who was treated with recombinant human G-CSF from age 3.5 years. His growth and development was normal, although complicated by intermittent infections. Bone mineral density (BMD) measurement revealed severe osteopenia at the spine and hips (lumbar spine BMD 0.486 g/cm(2); Z score -3.6), and he was referred to the Endocrine Service. Relevant laboratory evaluation showed a pretreatment ionized calcium level at the upper limit of normal (1.28 mmol/L; range: 1.13-1.32 mmol/L), suppressed intact parathyroid hormone (iPTH) level (12 pg/mL; range: 10-65 pg/mL), and a low 1,25-dihydroxy vitamin D level (21 pg/mL; range: 24-65 pg/mL). He had evidence of increased bone turnover evidenced by elevated urinary deoxypyridinoline (DPD) cross-links (46.9 nmol/mmol creatinine; range: 2-34 nmol/mmol creatinine) and a simultaneous increase in markers of bone formation with elevated osteocalcin level (200 ng/mL; normal: 20-80 ng/mL) and alkaline phosphatase level (236 IU/mL; normal: 38-126 IU/mL). Because of clinical concern for his skeletal health, bisphosphonate therapy with intravenous pamidronate was initiated. One month after treatment, the iPTH and DPD cross-links were in the normal range (54 pg/mL and 17.7 nmol/mmol creatinine, respectively) and the 1,25-dihydroxy vitamin D level was elevated (111 pg/mL). Four months after treatment, there was a striking increase in BMD at the lumbar spine (+30.86%), femoral necks (left, +20.02%; right, +17.98%), and total hips (left, +18.40%; right, +15.94%). Seven months after bisphosphonate therapy, his biochemical parameters showed a return toward pretreatment levels with increasing urinary DPD cross-links (28.7 nmol/mmol creatinine) and decreasing iPTH (26 pg/mL). However, the BMD continued to increase (8 months posttreatment), but the magnitude of the increment was attenuated (lumbar-spine, +4.8%; left total hip, +1.2% and right total hip +2.4%), relative to BMD at 4 months. Eight months after the initial treatment, his iPTH was suppressed at 14 pg/mL and he again received pamidronate (at a lower dose); 3 months later, he had an additional increase in BMD (lumbar spine +7.4%, left total hip +3.9%, right total hip +2.7%), relative to the previous study. We hypothesize that prolonged administration of G-CSF as treatment for Kostmann's syndrome is associated with increased bone resorption, mediated by osteoclast activation and leading to bone loss. In children, the resulting osteopenia can be successfully managed with antisreorptive bisphosphonate therapy with significant improvement in bone density. Measurements of biochemical parameters of bone turnover can be used to monitor the magnitude and duration of the therapeutic response and the need for BMD reassessment and, perhaps, retreatment." @default.
• W2107436520 created "2016-06-24" @default.
• W2107436520 creator A5029812690 @default.
• W2107436520 creator A5051301363 @default.
• W2107436520 creator A5053233007 @default.
• W2107436520 creator A5055291561 @default.
• W2107436520 creator A5069623729 @default.
• W2107436520 creator A5081199436 @default.
• W2107436520 date "2001-09-01" @default.
• W2107436520 modified "2023-10-10" @default.
• W2107436520 title "Severe Osteopenia in a Young Boy With Kostmann's Congenital Neutropenia Treated With Granulocyte Colony-Stimulating Factor: Suggested Therapeutic Approach" @default.
• W2107436520 cites W1768011742 @default.
• W2107436520 cites W1948868238 @default.
• W2107436520 cites W1963594703 @default.
• W2107436520 cites W1967508781 @default.
• W2107436520 cites W1975447125 @default.
• W2107436520 cites W1978444530 @default.
• W2107436520 cites W2000605416 @default.
• W2107436520 cites W2006950202 @default.
• W2107436520 cites W2007622343 @default.
• W2107436520 cites W2011785865 @default.
• W2107436520 cites W2012207856 @default.
• W2107436520 cites W2014188685 @default.
• W2107436520 cites W2022851031 @default.
• W2107436520 cites W2023173170 @default.
• W2107436520 cites W2024016372 @default.
• W2107436520 cites W2040774493 @default.
• W2107436520 cites W2043645968 @default.
• W2107436520 cites W2048299560 @default.
• W2107436520 cites W2051133695 @default.
• W2107436520 cites W2053028785 @default.
• W2107436520 cites W2063048904 @default.
• W2107436520 cites W2069251613 @default.
• W2107436520 cites W2073037082 @default.
• W2107436520 cites W2095095686 @default.
• W2107436520 cites W2105788132 @default.
• W2107436520 cites W2109240651 @default.
• W2107436520 cites W2140365825 @default.
• W2107436520 cites W2140473585 @default.
• W2107436520 cites W2163724450 @default.
• W2107436520 cites W2329575366 @default.
• W2107436520 cites W2343211135 @default.
• W2107436520 cites W2401078586 @default.
• W2107436520 cites W4233481492 @default.
• W2107436520 cites W4235278189 @default.
• W2107436520 cites W4367483747 @default.
• W2107436520 cites W4376542787 @default.
• W2107436520 doi "https://doi.org/10.1542/peds.108.3.e54" @default.
• W2107436520 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11533372" @default.
• W2107436520 hasPublicationYear "2001" @default.
• W2107436520 type Work @default.
• W2107436520 sameAs 2107436520 @default.
• W2107436520 citedByCount "23" @default.
• W2107436520 countsByYear W21074365202012 @default.
• W2107436520 countsByYear W21074365202013 @default.
• W2107436520 countsByYear W21074365202019 @default.
• W2107436520 countsByYear W21074365202021 @default.
• W2107436520 crossrefType "journal-article" @default.
• W2107436520 hasAuthorship W2107436520A5029812690 @default.
• W2107436520 hasAuthorship W2107436520A5051301363 @default.
• W2107436520 hasAuthorship W2107436520A5053233007 @default.
• W2107436520 hasAuthorship W2107436520A5055291561 @default.
• W2107436520 hasAuthorship W2107436520A5069623729 @default.
• W2107436520 hasAuthorship W2107436520A5081199436 @default.
• W2107436520 hasBestOaLocation W21074365201 @default.
• W2107436520 hasConcept C124490489 @default.
• W2107436520 hasConcept C126322002 @default.
• W2107436520 hasConcept C131075544 @default.
• W2107436520 hasConcept C134018914 @default.
• W2107436520 hasConcept C160160445 @default.
• W2107436520 hasConcept C181199279 @default.
• W2107436520 hasConcept C185592680 @default.
• W2107436520 hasConcept C2776541429 @default.
• W2107436520 hasConcept C2776694085 @default.
• W2107436520 hasConcept C2776886416 @default.
• W2107436520 hasConcept C2777063308 @default.
• W2107436520 hasConcept C2777083390 @default.
• W2107436520 hasConcept C2777767877 @default.
• W2107436520 hasConcept C2780787237 @default.
• W2107436520 hasConcept C55493867 @default.
• W2107436520 hasConcept C71924100 @default.
• W2107436520 hasConceptScore W2107436520C124490489 @default.
• W2107436520 hasConceptScore W2107436520C126322002 @default.
• W2107436520 hasConceptScore W2107436520C131075544 @default.
• W2107436520 hasConceptScore W2107436520C134018914 @default.
• W2107436520 hasConceptScore W2107436520C160160445 @default.
• W2107436520 hasConceptScore W2107436520C181199279 @default.
• W2107436520 hasConceptScore W2107436520C185592680 @default.
• W2107436520 hasConceptScore W2107436520C2776541429 @default.
• W2107436520 hasConceptScore W2107436520C2776694085 @default.
• W2107436520 hasConceptScore W2107436520C2776886416 @default.
• W2107436520 hasConceptScore W2107436520C2777063308 @default.
• W2107436520 hasConceptScore W2107436520C2777083390 @default.
• W2107436520 hasConceptScore W2107436520C2777767877 @default.
• W2107436520 hasConceptScore W2107436520C2780787237 @default.
• W2107436520 hasConceptScore W2107436520C55493867 @default.
• W2107436520 hasConceptScore W2107436520C71924100 @default.
• W2107436520 hasIssue "3" @default.

• next